CN109563060A - Ido1抑制剂及其制备方法和应用 - Google Patents

Ido1抑制剂及其制备方法和应用 Download PDF

Info

Publication number
CN109563060A
CN109563060A CN201780039482.3A CN201780039482A CN109563060A CN 109563060 A CN109563060 A CN 109563060A CN 201780039482 A CN201780039482 A CN 201780039482A CN 109563060 A CN109563060 A CN 109563060A
Authority
CN
China
Prior art keywords
compound
alkyl
pharmaceutically
optionally
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780039482.3A
Other languages
English (en)
Other versions
CN109563060B (zh
Inventor
张杨
付志飞
罗妙荣
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Luye Pharmaceutical Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Publication of CN109563060A publication Critical patent/CN109563060A/zh
Application granted granted Critical
Publication of CN109563060B publication Critical patent/CN109563060B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

一类作为吲哚胺‑2,3‑双加氧酶1(IDO1)抑制剂的化合物，及其在与IDO1相关疾病领域的应用。具体为式(Ⅰ)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201780039482.3A 2016-08-02 2017-08-02 Ido1抑制剂及其制备方法和应用 Active CN109563060B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610631523 2016-08-02
CN2016106315235 2016-08-02
CN2016107976220 2016-08-30
CN201610797622 2016-08-30
PCT/CN2017/095571 WO2018024208A1 (zh) 2016-08-02 2017-08-02 Ido1抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN109563060A true CN109563060A (zh) 2019-04-02
CN109563060B CN109563060B (zh) 2021-01-01

Family

ID=61073210

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780039482.3A Active CN109563060B (zh) 2016-08-02 2017-08-02 Ido1抑制剂及其制备方法和应用

Country Status (11)

Country Link
US (1) US20190169140A1 (zh)
EP (1) EP3495354A4 (zh)
JP (1) JP2019527699A (zh)
KR (1) KR20190034318A (zh)
CN (1) CN109563060B (zh)
AU (1) AU2017306487A1 (zh)
BR (1) BR112019001980A2 (zh)
CA (1) CA3032544A1 (zh)
RU (1) RU2019104899A (zh)
SG (1) SG11201900868XA (zh)
WO (1) WO2018024208A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107033097A (zh) * 2016-02-04 2017-08-11 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CN109942565A (zh) * 2017-12-20 2019-06-28 成都海创药业有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3389783A4 (en) 2015-12-15 2019-05-15 Merck Sharp & Dohme Corp. NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
UY37466A (es) 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
WO2018214958A1 (zh) * 2017-05-25 2018-11-29 山东绿叶制药有限公司 Ido1抑制剂的晶型及其制备方法
WO2019149159A1 (zh) * 2018-02-02 2019-08-08 山东绿叶制药有限公司 一种包含噁二唑类衍生物的组合物及其制备方法和应用
CN110143955B (zh) * 2018-02-11 2023-01-20 中国科学院上海药物研究所 含杂环侧链的噁二唑衍生物、合成方法及其应用
CN110343098B (zh) * 2018-04-04 2023-05-26 中国科学院上海药物研究所 一类噁二唑类化合物及其制备方法、药物组合物和用途
CN110407765B (zh) * 2018-04-28 2022-12-06 上海挚盟医药科技有限公司 1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用
CN109438513B (zh) * 2018-10-25 2020-05-12 中国药科大学 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用
CN112315954A (zh) * 2020-11-24 2021-02-05 烟台大学 紫杉醇和ido1小分子抑制剂复方药物组合物及其用途
CN114409610B (zh) * 2022-03-29 2022-06-10 山东大学 噁二唑衍生物及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105481789A (zh) * 2014-09-15 2016-04-13 中国科学院上海有机化学研究所 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
CN105646389A (zh) * 2016-01-28 2016-06-08 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
CN106565696A (zh) * 2015-10-09 2017-04-19 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2017106062A1 (en) * 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006244068B9 (en) * 2005-05-10 2012-10-25 Incyte Holdings Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
US8450351B2 (en) * 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
KR101783004B1 (ko) * 2008-07-08 2017-09-28 인사이트 홀딩스 코포레이션 인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
WO2018072697A1 (zh) * 2016-10-17 2018-04-26 上海医药集团股份有限公司 含噁二唑环化合物、制备方法、中间体、组合物及应用
UY37466A (es) * 2016-11-03 2018-01-31 Phenex Discovery Verwaltungs Gmbh N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa
WO2018214958A1 (zh) * 2017-05-25 2018-11-29 山东绿叶制药有限公司 Ido1抑制剂的晶型及其制备方法
WO2018228381A1 (zh) * 2017-06-13 2018-12-20 山东绿叶制药有限公司 1,2,5-恶二唑化合物制备方法及其中间体
WO2019047920A1 (zh) * 2017-09-08 2019-03-14 山东绿叶制药有限公司 作为ido1抑制剂的噁二唑类衍生物的晶型及其制备方法
WO2019149159A1 (zh) * 2018-02-02 2019-08-08 山东绿叶制药有限公司 一种包含噁二唑类衍生物的组合物及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105481789A (zh) * 2014-09-15 2016-04-13 中国科学院上海有机化学研究所 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
CN106565696A (zh) * 2015-10-09 2017-04-19 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2017106062A1 (en) * 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
CN105646389A (zh) * 2016-01-28 2016-06-08 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107033097A (zh) * 2016-02-04 2017-08-11 江苏恒瑞医药股份有限公司 噁二唑类衍生物、其制备方法及其在医药上的应用
CN109942565A (zh) * 2017-12-20 2019-06-28 成都海创药业有限公司 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
RU2019104899A3 (zh) 2020-08-21
EP3495354A4 (en) 2020-01-15
JP2019527699A (ja) 2019-10-03
CN109563060B (zh) 2021-01-01
BR112019001980A2 (pt) 2019-05-07
KR20190034318A (ko) 2019-04-01
CA3032544A1 (en) 2018-02-08
US20190169140A1 (en) 2019-06-06
RU2019104899A (ru) 2020-08-21
EP3495354A1 (en) 2019-06-12
WO2018024208A1 (zh) 2018-02-08
SG11201900868XA (en) 2019-02-27
AU2017306487A1 (en) 2019-02-21

Similar Documents

Publication Publication Date Title
CN109563060A (zh) Ido1抑制剂及其制备方法和应用
JP7026196B2 (ja) Ｒｅｔの阻害剤
CN105085489B (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
CN105829312B (zh) 一种n-苄基色胺酮衍生物及其制备方法和应用
CN103848785B (zh) 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
CN110172051B (zh) IRE-1α抑制剂
CN109790166A (zh) 咪唑并吡啶化合物用于治疗癌症
CN108727307A (zh) 化合物及其使用方法
NZ525324A (en) Nitrogenous aromatic ring compounds
CN109415341A (zh) 作为TGF-βR1抑制剂的苯并三氮唑衍生的α，β不饱和酰胺类化合物
BR112012025496B1 (pt) composto inibidor quinase e composição farmacêutica que o compreende
CN108727363A (zh) 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
CN105153026B (zh) 含联芳基酰胺结构的索拉非尼衍生物及其制备方法和应用
CN109843890A (zh) 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2023083194A1 (zh) Wee1蛋白激酶降解剂及其用途
CN109942565B (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途
Yan et al. Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site
CN106231900B (zh) 化合物及其使用方法
TWI729094B (zh) 內磺醯胺化合物及其使用方法
CN112979613B (zh) 2-(1h-吡唑-3-基)吡啶衍生物及其制备方法和用途
CN103360407B (zh) 一种噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
CN108570038A (zh) 二氢喹喔啉类溴结构域识别蛋白抑制剂及制备方法和用途
CN110143955A (zh) 含杂环侧链的噁二唑衍生物、合成方法及其应用
CN113583007B (zh) 一种吡咯并嘧啶类btk抑制剂及其制备方法与应用
CN115594655A (zh) 色酮肟类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40001713

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant